Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20022RG" target="_blank" >RIV/61988987:17110/19:A20022RG - isvavai.cz</a>
Result on the web
<a href="http://www.haematologica.org/content/haematol/104/12/2358.full.pdf" target="_blank" >http://www.haematologica.org/content/haematol/104/12/2358.full.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2019.224204" target="_blank" >10.3324/haematol.2019.224204</a>
Alternative languages
Result language
angličtina
Original language name
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
Original language description
Adoptive cellular therapy using chimeric antigen receptor T-cell (CAR-T) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved in relapsed/refractory MM, it will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in MM, and discusses several important issues for its future development.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
HAEMATOLOGICA
ISSN
0390-6078
e-ISSN
—
Volume of the periodical
104
Issue of the periodical within the volume
12
Country of publishing house
IT - ITALY
Number of pages
3
Pages from-to
2358-2360
UT code for WoS article
000499687600020
EID of the result in the Scopus database
2-s2.0-85075330452